1	HIV VITAL NON-Suppression and its Associated Factors Among PWITCI Mothers Receiving
2	ARV Treatment in Ethiopia.
3	Belete Woldesemayat <sup>1*</sup> , Ajanaw Yizengaw <sup>1</sup> , Aschale Worku <sup>2</sup> , Amelework Yilma <sup>1</sup> , Sisay
4	Adane <sup>1</sup> , Jaleta Bulti <sup>1</sup> , Eleni Kidane <sup>1</sup> , Gutema Bulti <sup>1</sup> , Saro Abdella <sup>1</sup>
5	
6 7	<ol> <li>HIV AIDS and TB directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia</li> <li>Federal Ministry of Health, Addis Ababa, Ethiopia</li> </ol>
8	
9 10	*Corresponding author: <a href="mailto:beleteweldesemeyat@gmail.com">beleteweldesemeyat@gmail.com</a> , Ethiopian Public Health Institute, Arbegnoch Street, Addis Ababa, Ethiopia. PoBox: 1242.
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	

### **Abstract**

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

**Background:** Pediatric HIV infection is mainly caused by Mother-to-child transmission (MTCT). Without any effective medical intervention, 15-45% of infants born to HIV-positive women will become infected with HIV. The contribution of viral non-suppression for MTCT is high. Hence, this study was to determine the magnitude of HIV viral non-suppression, and associated factors among PMTCT Mothers in Ethiopia. **Methods:** The study was conducted from April 1, 2023, to December 31/2024 at 16 public health facilities. An institutional-based cross-sectional study was employed and 496 HIV-positive pregnant and lactating women on ART were included. Data was collected using a prechecked questionnaire with paper mode and ODK (Open Data Kit) for each participant. Venous blood was collected using two Ethylenediamine Tetra acetic Acid (EDTA) tubes for HIV viral load, CD4 and Hgb test. HIV viral load tests were conducted at the EPHI (Ethiopian Public Health Institute) National HIV reference laboratory using the COBAS 4800 System (Roche Molecular Diagnostics). Data was edited and exported to SPSS from the ODK data file, and finally data analysis was performed using SPSS version 26 software. **Results:** 496 PMTCT Mothers were included in this study, the prevalence of HIV viral nonsuppression was 2.2% (95% CI; 1.1-3.9), the rate of viral detectability was 21.8 % (95% CI; 18.2-25.7) and the rate of low-level viremia (LLV) was 9.1%. Family size ( $X^2=7.20$ ; p<0.001), a poor and fair level of Adherence ( $X^2=18.553$ ; p<0.001), exposure to opportunistic infection ( $X^2=25.29$ ; p<0.001), survey time WHO clinical stages II & III (X<sup>2</sup>=25.29; p<0.001), HIV status nondisclosure other than Health care workers (HCWs) (X<sup>2</sup>=4.408; p=0.036), and low survey time CD4

42 count (<350 cells/ul) (  $X^2=15.989$ ; p<0.001) were significantly associated to the rate of HIV viral non-suppression. 43 44 **Conclusions:** In this study, HIV viral non-suppression among pregnant and lactating women is 45 relatively low (meet the UNAIDS 2030 target). However, Family size, level of Adherence, exposure to opportunistic infection, WHO clinical stage level II and III, HIV status disclosure and 46 47 low CD4 count were significantly associated with the prevalence of viral non-suppression. To achieve persistent HIV viral suppression enhanced adherence and counselling services should be 48 provided, tailored to the needs of the specific target group. 49 50

**Keywords:** Associated factors, PMTCT, HIV viral non-suppression, Low-level viremia

### 1. Introduction

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

Mother-to-child transmission (MTCT) of HIV is the primary mode of HIV infection in children and paediatrics [1]. Without any effective medical intervention approximately 15-45% of infants born from HIV-positive women will become infected with HIV, out of these about 5-15% of them are got the infection with breastfeeding [2]. One of the biological risk factors of vertical transmission of HIV is related to the high maternal viral burden, which is a significant predictor of transmission especially when an HIV viral load of more than 1000 Ribonucleic Acid (RNA) copies per one millilitre of plasma [3-4]. In a collaborative prospective study from seven European countries and the United States, MTCT prevalence among anti-retroviral treated women with a viral RNA level of fewer than 1000 copies at close to delivery was only one percent (95% CI; 0.4%–1.9%) [5]. HIV viral load (VL) has a central role in determining MTCT risk, in addition to this; viral lowering or suppression is strongly associated with decreased HIV disease progression, and prevention of sexual transmission. Even if there is a limitation on PMTCT service coverage in developing countries, viral suppression was registered after ART initiation in HIV-infected pregnant women, particularly in sub-Saharan Africa [6]. The year between 2009 and 2014, 89% of infants were prevented with the provision of Anti-retroviral treatment (ART) medication for pregnant and breastfeeding women in 21 high-priority sub-Saharan countries [7]. HIV viral suppression is one of United Nations AIDS's (UNAIDS's) targets (95-95-95) to end AIDS epidemics by 2030. The third 95 indicate that at least 95% of those on ART should be virologically suppressed (<1000 RNA copies/ml), translating into a final target of at least 73% and 86% of all PLWH (people living with HIV) achieving virologic suppression [8-9]. It will

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

to near-zero levels by 2030 [10]. However, until now there are a lot of impediments, like attitude and behavioural problems towards ART medication, physiological change (e.g. pregnancy) and co-infection with infectious disease (e.g. Syphilis) to achieve the above attainments [11]. On the other hand, different studies showed that because of different factors virological nonsuppression and drug resistance are more common in pregnant women than non-pregnant mothers [12-14]. According to the Ethiopian national HIV/AIDS strategic plan, the main way of MTCT is during breastfeeding, which 0.33% of infants were exposed because of the late start of ART during pregnancy, 3.83% of cases were due to dropped off ART from 14,000 spectrum cases [15]. To achieve the optimal protection of MTCT of HIV, early identification (starting from the first antenatal care visit) and during the postnatal period of viral non-suppression during pregnancy and lactating period is very crucial. Many studies have reported on the HIV viral suppression rate and associated factors among non-PMTCT Mothers populations, however, the magnitude of HIV viral non-suppression in this study area and also limited study was reported in our country. Therefore, this study aims to assess the magnitude of viral non-suppression and its associated factors as programs aim for universal access among pregnant and lactating women whose viral load level was non-suppressed in Ethiopia.

#### 2. Materials and Methods

#### 2.1. Study design and area

An institutional-based cross-sectional study was conducted from April 1/ 2023 to December 31/ 2023 in Addis Ababa, Ethiopia's capital city, located at 901'48"N 380 44'24"E/9.030000N 98.740000E. According to the Central Statistical Authority of Ethiopia in 2021 population estimation, Addis Ababa has a total population of 3,774,000 people (1,782,000 male and 1,992,000 female), with an annual growth rate of about 2.4%. The city is located in the country's heartland and is organized into 11 administrative sub-cities (Addissketma, Akaki Kality, Arada, Bole, Gullele, Kirkos, KolfieKeranio, Lideta, Niafas Silk-lafto, Yeka and Lemi-Kura). The health Bureau was in authority of the city's overall health activities. Numerous clinics, health centres, and hospitals offer medical services [16]. According to Ethiopian Health and Health Related Indicators, there were 78,106 anticipated pregnancies in Addis Ababa and 105,086 delivered by a trained attendant [17].

#### 2.1. Study population

All HIV-positive pregnant and lactating mothers, who have been taking ART for at least 6 months and were delivered or come to the health facility for Antenatal care (ANC) and or postnatal care (PNC) services in Sixteen (16) selected health institutions in Addis Ababa and given consent for data and sample collection were recruited in this study. Health facilities (HFs) included in this study have been selected purposively based on their PMTCT client load. We included 5 governmental hospitals, 10 health centres and 01 non-governmental health centre. At the end of the 2022/23 budget year, the total number of PMTCT clients in Addis Ababa was 1041. A total of 16 health facilities were included in this study. Sample size determination was estimated based on a single population proportion by considering different assumptions including, the previous study conducted in West Shewa, Ethiopia, the proportion of viral non-

rate were considered. The final sample size was 510, and the data were collected from 496

participants in the study period.

#### 2.2. Data Collection

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

Data was collected from 496 study participants by trained health professionals (1 laboratory personnel and 1 nurse/health officer) from ANC and PNC clinics in the selected health facilities. Additional training was given for data collectors on data collection using ODK. laboratory sample collection, sample handling, and storage. Pre-checked questionnaires were filled properly with ODK and paper forms. Sociodemographic (Age, Marital status, Education, Employment status, Family size), clinical and behavioural determinants (Disclosure, Adherence, WHO clinical stage, ART duration, ART regimen, CD4 count, HIV disclosure, Use of memory aids, Use of alternative medicine, Use of alcohol and Substance abuse) and Pregnancy-related variables (Gestational age, Parity, Anemic condition) variables were collected properly. All CD4, Haemoglobin and Syphilis tests were performed during the survey time by the previously existing referral system or in their facility laboratory. After the tests were performed the result was entered and sent by ODK. Ten (10) millilitre venous blood was collected by using two Ethylene diamine Tetra acetic acid (EDTA) tubes and the plasma sample was separated and prepared immediately within 6 hours of after sample collection according to sample collection and transportation guidelines and stored 2-8 °C. All plasma samples were transported to the EPHI HIV national reference laboratory within 5 days for HIV viral load testing. If the sample was not tested within 5 days after collection, it was stored at -70 °C. Socio-demographic, clinical and other questionnairebased information was collected by trained nurses or health officers and sample collection,

- 143
- and sample transportation delegated from EPHI. 144

#### 2.3. Laboratory methods

#### HIV viral load

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

Viral load testing was conducted at EPHI National HIV Reference Laboratory (NRHIVL) using the Cobas 4800 system (Roche Molecular Diagnostics, Pleasanton CA, USA, 2016 Roche Molecular Systems, Inc.). In clinical specimens, the COBAS Real-Time HIV-1 Quantitative RT-PCR creates the amplified product from the HIV-1 RNA genome, in the process of sample extraction the Cobas 4800 system uses OS (Quantification Standard), an RNA sequence unrelated to the HIV-1 target sequence is added to each specimen. This unrelated RNA sequence is amplified simultaneously with the target sequence by Real-time polymerase chain reaction (RT-PCR) to ensure the sample preparation and amplification procedures are working properly. Using fluorescent-labelled oligonucleotide probes, the COBAS 4800 system analyzes the quantity of HIV-1 target sequence present during each amplification cycle. The probes do not create a signal until they are directly connected to the amplified product. The amplification cycle at which the 4800z detects fluorescence light is proportional to the amount of HIV-1 RNA contained in the original sample. The COBAS 4800 RT system measures the quantity of HIV-1 target sequence present at each amplification cycle using fluorescent-labeled oligonucleotide probes. The fluorescent signal recorded by the PCR machine is proportional to the copies of the HIV-1 RNA concentration in the original sample during the amplification cycle. We used a 0.4 millilitre (ml) sample volume, the lower detection limit is 20 RNA copies per one ml of plasma [19].

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

medRxiv preprint doi: https://doi.org/10.1101/2024.06.13.24308915; this version posted June 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license. 2.4. Operational definition PMTCT Mothers: Pregnant and lactating women who were taking ARV treatment in the **PMTCT** clinics **Viral non-suppression:** ≥1000 RNA copies/ml after ART treatment in the plasma sample Viral Detectability: Viral load result ≥20 RNA copies/ml in the COBAS 4800 system Low-level viremia: Viral load 50 to 999 RNA copies/ml Good Adherence: Participants take medications at prescribed times and frequencies, and follow restrictions regarding food and other medications at least 95%. Poor Adherence: participants take medications at prescribed times and frequencies, and follow restrictions regarding food and other medications less than 95%. 2.5. Data processing and analysis Data was edited and entered into the computer using SPSS software version 26. The summary of descriptive statistics for all dependent and independent variables was done with crosstabulation and Chi-square analysis. The association between quantitative variables associated with the viral un-suppression was performed using Non-parametric Mann-Whitney U analysis, P values were done and P < 0.05 was considered a significant association. 2.6. Ethical Approval Ethical clearance was obtained from the Ethiopian Public Health Institute Scientific Ethical Review Board with the protocol number EPHI-IRB-436-2022. Written informed consent was taken from each study participant. The responders' personal information was kept private and confidential except for the authors.

#### 3. Results

#### 3.1. Socio-demographic characteristics of HIV positive Pregnant and

Lactating women

In this study 496 participants were included from 16 health facilities; which comprised 5 hospitals, 10 governmental health centres and one non-governmental health centre. The total response rate was 97.3%. Out of 496 participants, 265 (53.4%) were below the age of 30 years, and the mean age of participants was  $30.96 \pm 5.24$  (Standard deviation). 153 (30.8%) of participant's educational status was primary school, 81 (16.3%) had no formal education and 74 (14.9%) of participants' educational status was college or university. The majority of participants, 427 (86.1%) were Married, 384 (77.4%) were Orthodox Christians, 273 (55%) were housewives and many participants, 285 (57.5%) had family sizes were 3-4 (**Table 1**).

#### 3.2. Clinical and Behavioral Characteristics of Study Participants

Among 496 participants 138 (27.8%) had discordant HIV results, whereas almost half of the participants 244 (49.2%) had the same result (HIV-positive) with their partners. The majority, 455 (91.7%) of participants received regular ART supplies for the last 6 months. Similarly, 465 (93.8%), 461 (92.9%), and 443 (89.3%) participants had good adherence, WHO clinical stage I and had not used any alcohol or other substance for the last month respectively. Out of 496 subjects, 304 (61.3%) had a habit of using memory aid to take ART medicine. On the other hand, among 356 participants who were receiving previous ART regimens the majority, 320 (89.9%) were receiving TDF + 3TC + EFV (**Table 2**).

In this study for the last 6 months 211 (42.5%) of participants were skipping/stopping ARV medication once or more than once. Out of these 211 participants, 82 (16.5%) skipped/stopped their medication due to they forgot/busy. Similarly, 0.8%, 3.6%, 0.4 %, and 2% skipped/missed

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

respectively (**Figure 1**). According to Figure 2, 455 (91.7%) participants received the new DTG-based ART regimen (TDF, 3TC, DTG). Whereas, 17 (3.4%), 8 (1.6%) and 7 (1.4%) participants were taking ART drugs including, TDF + 3TC + ATV/r, ABC+ 3TC + LPV/r, and TDF + 3TC + EFV respectively. 32 (6.5%) of ART patients were receiving a second-line regimen and the rest 464 (93.5%) were taking a first-line treatment regimen (**Figure 2**). According to the obstetrics characteristics of study participants, 320 (64.5%) were lactating women and the rest 176 (35.5%) were HIV-positive pregnant women. Among pregnant women, 11 (6.3%) were in the first trimester and 84 (47.7%) were in the third trimester. 194 (39.1%) of participants had their pregnancy for the first time (primigravida). The majority of participants had 0-1 child (73%), did not have any types of chronic illness (98.2%), had good MUAC measurement (95.4%),  $\geq$  350 CD4 cells/ul (93.3%) and a negative syphilis antibody test (97.2%) (**Table 3**). 3.3. Prevalence of HIV-1 viral non-suppression, viral undetectability and low-level viremia Among 496 HIV-infected pregnant and lactating women who are receiving ART, 11 (2.2%; 95% CI; 1.1 – 3.9) had virologically not suppressed (HIV VL≥1000 copies/ml). The remaining 485 (97.8%) study participants had successfully suppressed viral load (Figure 3A). In this study, the magnitude of viral undetectability was 21.8 % (95% CI; 18.2-25.7) (**Figure 3B**). All participants taking first-line or second-line ARV treatment during the survey time were included. The low-level viremia (LLV) (50-999 RNA copies/ml) magnitude of this study was 9.1% (45/496). Participants whose viral load was from 20-50 RNA copies/ml were 52 (10.5%) (Figure 4).

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

To determine the associated risk factors of HIV-1 viral non-suppression among pregnant and lactating women who were receiving option B+ in the PMTC department in Addis Ababa Health facilities. Socio-demographic, clinical, behavioural, nutritional, obstetric, and immunological determinants were included. To determine the socio-demographic risk factors for the viral non-suppression group among the participants, except family size, all independent variables including; age, marital status, type of health facility, educational status, religious view and occupational status were not significantly associated with non-viral suppression. Regarding family size the proportion of HIV-1 viral non-suppression was high who had a high family size (>4) and according to chi-square analysis the family size is significantly associated with non-viral suppression ( $X^2=7.20$ ; P=0.027). Regarding clinical and behavioural risk factors, participants who had poor adherence and fair adherence were found high proportion of viral non-suppression, poor 1(9.1%) Fair 3(15.0 %). the chi-square analysis showed that Adherence was significantly associated with viral nonsuppression (X<sup>2</sup>=18.553; p<0.001). Opportunistic infections during the survey time were significantly associated with viral non-suppression (X<sup>2</sup>=25.290; P<0.001). WHO clinical stage II and III had a high proportion of viral non-suppression (14.3%) compared to WHO clinical stage I (1.3%), the chi-square test also showed that significantly associated with viral nonsuppression (X<sup>2</sup>=25.29; P<0.001). Similarly, participants who didn't disclose their HIV status other than HCWs were one of the associated factors for HIV-1 viral non-suppression (X<sup>2</sup>= 4.408; P=0.036). The rate of viral non-suppression in patients whose CD4 count was less than 350 cells/ul was 12.1%, whereas the rate of viral non-suppression among those whose CD4 count >350 cells/ul in the survey time was 1.5%. Therefore the chi-square analysis showed that CD4 count is significantly associated with HIV-1 viral non-suppression (X<sup>2</sup>=15.989; P<0.001) (**Table 4**).

once in the last 6 months. 6 (3%) of those HIV-1 viral loads were ≥1000 RNA copies/ml, while the rest of the viral suppression among these patients was 97% (n=205). Being forgotten/busy, running out of pills, depression, food shortage, and feeling better have had some associations with the rate of viral non-suppression. However, based on logistic regression analysis the associations were not reached at the significant level (p>0.05) (**Figure 5**). According to independent T-test analysis, except for CD4 T cells, all the other parameters (Hgb, MUAC, Age and duration on ART) were not statistically significant association with HIV-1 viral non-suppression. The mean value of CD4 T cell count in the viral non-suppression group was 427 cells/ul and in the suppressed group was 557.85 cells/ul which indicated that the non-suppressed group CD4 is significantly lower compared to the suppressed group (P=0.013)(Figure 6). Similarly, the non-parametric Mann-Whitney U analysis showed that only CD4 T cells are significantly associated with HIV-1 Viral non-suppression (**Table 5**).

#### 4. Discussion

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

HIV viral non-suppression is a key factor for HIV transmission through vertically or horizontally. The risk of transmission is null to very low if the HIV viral suppression is successful for people who are taking ARV medication. So, to create an AIDS-free generation monitoring viral suppression, enhanced Adherence and counselling in ART drugs, early case detections are the main issues in HIV/AIDS control and prevention programs. Moreover, in HIV-infected women who are taking ARV treatment and could maintain their HIV-1 viral load <1000 RNA copies/ml in pregnancy, delivery and breastfeeding, the mother-to-child HIV transmission could be very low (<%1). Similarly, if their viral load is maintained undetectable throughout their PMTCT period the vertical transmission is almost zero [20]. Our study evaluated the magnitude of HIV-1 Viral non-suppression and associated factors among HIVpositive pregnant and lactating women who are taking ARV treatment for at least six months. In this study, the prevalence of HIV-1 viral non-suppression was 2.2 % (95% CI; 1.1-3.9), viral detectability was 21.8 % (95% CI; 18.2-25.7) and the magnitude of low-level viremia (LLV) (50-999 RNA copies/ml) was 9.1%. This result is in line with the study conducted in Northern Ethiopia, where the rate of viral non-suppression among pregnant women was 1.31% [21], and a study reported from South Africa, showed that viral non-suppression among women on ART was 4.1% [21]. Similarly, in another study from Northeastern South Africa, the rate of lowlevel viremia was quite similar to our study (13.8%) [23]. Also, the prevalence of detectable viral load was reported as 17.3 % in Malawi [24]. On the contrary, many previous studies showed that the prevalence of viral non-suppression among pregnant and lactating women was high including in, the Amhara region, Ethiopia (9.1%) [25], Rural South Africa (14.7%) [23], Rural Uganda (19%) [26], Southern and Central Malawi (16%) [27], Mazowe, Zimbabwe (5.6%) [28], Malawi (13.5%) [29], and 12.1% study from Kenya [30]. Our study showed that

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

to the follow-up of PMTCT women increased due to their obstetrics conditions and access to PMTCT service expansion. Additionally, other differences including; type of population, adherence level of the population, geographical and cultural differences and some studies that include ART naïve participants might be the reason for high viral non-suppression. Viral load monitoring programs in the country among PMTCT clients may have a huge impact on viral load suppression, the local health system and program focus could affect the suppression rate [31]. Even though, the prevalence of low viral non-suppression was recorded, it had a critical impact on the program as well as for the offspring since HIV transmission is very high, the recent cohort study result also showed that the risk of HIV transmission was nine times more likely to transmit to the baby if the viral load result is non-suppressed in the time of pregnancy or breastfeeding [32]. Pregnant and lactating mothers whose HIV viral non-suppression was significantly associated with the level of Adherence, presence of opportunistic infection, HIV status disclosure status, family size and CD4 count. These results are supported by many studies which were performed in Ethiopia as well as in different regions of the world. In this study, poor level of adherence and fair level of adherence showed a high proportion of non-viral suppression (14.8%;  $X^2=18.55$ ; P=<0.001), a significantly high proportion of non-viral suppression among poor adherence also reported from Amhara region, Ethiopia [25] and Kenya [30]. Exposure to opportunistic infection was one of the associated factors for HIV viral non-suppression in this study, which is in line with the results reported from Uganda [33] and Ethiopia [34], even though both studies were performed on all Adult HIV patients who were taking ART. The other important factor which is associated with viral non-suppression is the disclosure status of HIV other than health care workers, the proportion of non-disclosure groups is significantly high (4.5%; X<sup>2</sup>=4.41; p=0.036) compared to participants who disclosed those HIV

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

Kenya [30]. On the other hand, some studies indicated that disclosure status was not significantly associated with the prevalence of non-viral suppression [23, 35]. This difference might be related to cultural differences of the study population, for example, our study population had little or no habit of disclosing their result other than health care workers due to fright of discrimination. It leads to they might not taking their ARV medication to hide themselves from others. In a similar context, this study also revealed that the high numbers of family size (>4 people in the family) was significantly associated (high proportion of viral nonsuppression among these women) with viral non-suppression (4.5%;  $X^2 = 7.20$ ; p<0.001). The reason for this association might be related to the nutritional status of participants, even if this study showed that the MUAC measurement association did not reach the significant level with the viral non-suppression. In low-income countries high family size is significantly association with poverty and malnutrition [36]. In this study, CD4 count <350 cells/ul in the survey time was significantly associated with the HIV viral non-suppression (12.1 %, X<sup>2</sup> = 15.989; p<0.001) and the Non-parametric Mann-Whitney U analysis also showed that the viral non-suppression was significantly associated with low CD4 count (p=0.013). This result was concordant with the study in Northern Ethiopia, specifically CD4 count in survey time (< 200 cells/ul) was significantly associated with viral non-suppression [21]. On the other hand, the result reported in Uganda that baseline CD4 count was not associated with non-viral suppression [37]. The difference is related to the time of CD4 cell count because after ART treatment CD4 count could be reversed. In our study the other factor associated with HIV viral non-suppression was the WHO clinical stage of participants in survey time, the result showed that participants in clinical stage II and Stage III had a statistically significant association with viral non-suppression. 14.3% of participants who were in WHO clinical stages II and III were virally non-suppressed (≥ 1000

RNA copies/ml) ( X²= 25.29; p<0.001). In this study, there were no WHO clinical stage IV participants. This result is supported by the study conducted in Ethiopia [25]. According to different studies throughout the World HIV/AIDS disease progression, HIV viral replication and immune suppression (low CD4 count) had closely related outcomes [27, 38]. This study has some limitations including; Since it was an institution-based study we might not have included persons who had poor adherence to ARV drugs due to they had not any follow-up in the data collection period.

### 5. Conclusion

This study revealed that the prevalence of HIV viral non-suppression among pregnant and lactating women is relatively low and it showed that meeting the UNAIDS 2030 target. This performance might be related to the HIV prevention and control program implementation, specifically the PMTCT service improvement from time to time in pregnant and lactating women to prevent HIV transmission risks to their children. However, in this study Family size, level of Adherence, exposure to opportunistic infection, WHO clinical stage level II and III, HIV status disclosure and low CD4 value were significantly associated with the prevalence of viral non-suppression. Even though the prevalence rate was low, enhanced Adherence and counselling should be increased for specific groups of pregnant and lactating women like; women who have large family sizes and do not disclose their HIV status to immediate family members to achieve persistent HIV viral suppression.

## Acknowledgements

Our acknowledgement is forwarded to all staff of the Ethiopian Public Health Institute, the national HIV reference laboratory for valuable support for sample handling and laboratory analysis.

## **Funding**

377

397

378 This research received no specific grant from any funding institutions.

379	<b>Author Contributions</b>
380	Conceptualization: Belete Woldesemayat
381	Data curation: Belete Woldesemayat, Ajanaw Yizengaw
382	Formal analysis: Belete Woldesemayat, Ajanaw Yizengaw
383	Investigation: Amelework Yilma, Sisay Adane, Eleni Kidane
384	Methodology: Amelework Yilma, Sisay Adane, Gutema Bulti
385	Resources: Jaleta Bulti, Saro Abdella
386	Supervision: Belete Woldesemayat
387	Validation: Saro Abdella
388	Visualization: Belete Woldesemayat, Ajanaw Yizengaw
389	Writing – original draft: Belete Woldesemayat, Aschale Worku
390	Writing-review & editing: Belete Woldesemayat, Ajanaw Yizengaw, Aschale Worku,
391	Amelework Yilma, Sisay Adane, Eleni Kidane, Gutema Bulti, Jaleta Bulti, Saro Abdella,. All
392	authors have read and agreed to the published version of the manuscript.
393	
394	
395	
396	

Reference

398

415

416

417

418

419

420

421

- 1. Bucagu M, Bizimana J de D, Muganda J, Humblet CP. Socio-economic, clinical and biological risk factors for mother to child transmission of HIV-1 in Muhima health centre (Rwanda): a prospective cohort study. Arch Public Heal. 2013;71(4):1–12.
- 2. World Health Organization. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV and syphilis. World Health Organization; 2017.
- 3. Plaeger S, Bermudez S, Mikyas Y, Harawa N, Dickover R, Mark D, et al. Decreased

  CD8 Cell-Mediated Viral Suppression and Other Immunologic Characteristics of

  Women Who Transmit Human Immunodeficiency Virus to Their Infants. J Infect Dis.

  1999;179(6):1388–94.
- 4. Fischetti L, Danso K, Dompreh A, Addo V, Haaheim L, Allain JP. Vertical transmission of HIV in Ghanaian women diagnosed in cord blood and post-natal samples. J Med Virol. 2005;77(3):351–9.
- 5. Ioannidis JPAPA, Abrams EJJ, Ammann A, Bulterys M, Goedert JJJ, Gray L, et al.
  Perinatal Transmission of Human Immunodeficiency Virus Type 1 by Pregnant
  Women with RNA Virus Loads <1000 Copies/mL. J Infect Dis. 2001;183(4):539–45.
  - 6. Myer L, Phillips T, Ramjith J, Bekker LG, McIntyre JA, Abrams EJ. Viral suppression after antiretroviral therapy initiation in pregnancy in South Africa. In Abstract presented at the Conference on Retroviruses and Opportunistic Infections 2015 (pp. 23-26).
  - 7. UNAIDS M. Progress report on the global plan. Towards the elimination of new HIV infections among children by. 2015. Available from:

    http://www.unaids.org/sites/default/files/media\_asset/JC2774\_2015ProgressReport\_G

422 <u>lobalPlan en.pdf</u>

- 423
- towards the United Nations 90-90-90 and 95-95-95 targets: The experience in British 424
- Columbia, Canada. J Int AIDS Soc. 2017;20(3):1–9. 425
- 9. World Health Organization. Global action plan on HIV drug resistance 2017-2021: 426
- 2018 progress report, July 2018: executive summary. World Health Organization; 427
- 2018. 428
- 429 10. Dunaway K, Brion S, Hale F, Alesi J, Assan H, Chung C, et al. What will it take to
- achieve the sexual and reproductive health and rights of women living with HIV? 430
- 431 Women's Heal. 2022;18. https://doi.org/10.1177/1745505722108036.
- 11. Petty LA, Steinbeck JL, Pursell K, Jensen DM. Human immunodeficiency virus and 432
- coinfection with hepatitis B and C. Infect Dis Clin North Am. 2014 Sep;28(3):477-99. 433
- doi: 10.1016/j.idc.2014.05.005. PMID: 25151567. 434
- 12. Kingoo JM. HIV Treatment Failure Markers; Virologic Outcomes after 12 Months of 435
- Antiretroviral Therapy among Patients Receiving HAART in Busia County, Kenya 436
- (Doctoral dissertation, JKUAT-COPAS). 437
- 13. Read JS, Cohen RA, Hance LF, MacHado ES, Mussi-Pinhata MM, Ceriotto M, et al. 438
- Missed opportunities for prevention of mother-to-child transmission of HIV-1 in the 439
- NISDI Perinatal and LILAC cohorts. Int J Gynecol Obstet. 2012;119(1):70–5. 440
- 14. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. 441
- Factors Associated with Virological Non-suppression among HIV-Positive Patients on 442
- Antiretroviral Therapy in Uganda, August 2014-July 2015. BMC Infect Dis. 443
- 2017;17(1):1–11. 444
- 15. (FHAPCO) FH prevention and control office. HIV/AIDS National Strategic Plan (NSP) 445
- for Ethiopia 2021-2025. 2021. 446

Cent Stat Auth Ethiop. 2021.

- 17. Ethiopian Public Health Institute (EPHI) [Ethiopia]. Mini Demographic and Health 449
- Survey: key indicators [Internet]. Handbook of Federal Countries, 2005. 2019. 136-450
- 148 p. Available from: www.DHSprogram.com. 451
- 18. Demissie DB, Bulto GA, Mekuria WT, Dufera FN, Gamshe EN. Evaluation of 452
- 453 antiretroviral therapy initiated among pregnant women under option B+ by viral load
- and CD4 count outcomes in selected hospitals of West Shewa Zone, Oromia Region, 454
- 455 Ethiopia. HIV/AIDS-Research and Palliative Care. 2020 Mar 19:127-34.
- 19. World Health Organization. WHO Prequalification of In Vitro Diagnostics Public 456
- Report Product: cobas HIV-1 Quantitative nucleic acid test for use on the cobas 4800 457
- System. 2021. 1–65 p. 458
- 20. World Health Organization policy brief. The role of HIV viral suppression in improving 459
- individual health and reducing transmission: policy brief. Geneva: World Health 460
- Organization; 2023. Who. 2023; (ISBN 978-92-4-005517-9 (electronic version)):16. 461
- 21. Desta AA, Woldearegay TW, Futwi N, Gebrehiwot GT, Gebru GG, Berhe AA, et al. 462
- HIV virological non-suppression and factors associated with non-suppression among 463
- adolescents and adults on antiretroviral therapy in northern Ethiopia: A retrospective 464
- study. BMC Infect Dis. 2020;20(4):https://doi.org/10.1186/s12879-019-4732-6. 465
- 22. Ntombela NP, Kharsany AB, Soogun A, Yende-Zuma N, Baxter C, Kohler HP, 466
- McKinnon LR. Viral suppression among pregnant adolescents and women living with 467
- HIV in rural KwaZulu-Natal, South Africa: A cross-sectional study to assess progress 468
- towards UNAIDS indicators and Implications for HIV Epidemic Control. Reproductive 469
- Health. 2022;19(1):116. 470

medRxiv preprint doi: https://doi.org/10.1101/2024.06.13.24308915; this version posted June 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license.

23. Ngandu NK, Lombard CJ, Mbira TE, Puren A, Waitt C, Prendergast AJ, et al. HIV viral 471 load non-suppression and associated factors among pregnant and postpartum women in 472 rural northeastern South Africa: A cross-sectional survey. BMJ Open. 2022;12(3):1-473 12. 474 24. Chagomerana MB, Miller WC, Tang JH, Hoffman IF, Harrington BJ, DiPrete B, Wallie 475 S, Jumbe A, Limarzi L, Hosseinipour MC. Prevalence of antiretroviral therapy 476 477 treatment failure among HIV-infected pregnant women at first antenatal care: PMTCT Option B+ in Malawi. PLoS One. 2018;13(12):e0209052. 478 479 25. Endalamaw Alamneh D, Shiferaw MB, Demissie MG, Emiru MA, Kassie TZ, Lakew KE, et al. Virological Outcomes Among Pregnant Women Receiving Antiretroviral 480 Treatment in the Amhara Region, North West Ethiopia. HIV/AIDS - Res Palliat Care. 481 2023;15:209-16. 482 26. Koss CA, Natureeba P, Kwarisiima D, Ogena M, Clark TD, Olwoch P, et al. Viral 483 suppression and retention in care up to 5 years after initiation of lifelong art during 484 pregnancy (option b+) in rural Uganda. J Acquir Immune Defic Syndr. 485 2017;74(3):279-84. 486 27. Hosseinipour M, Nelson JAE, Trapence C, Rutstein SE, Kasende F, Kayoyo V, et al. 487 Viral suppression and HIV drug resistance at 6 months among women in Malawi's 488 option B+ program: Results from the PURE Malawi study. J Acquir Immune Defic 489 490 Syndr. 2017;75(2):S149-55.

- 28. Nyakura J, Shewade HD, Ade S, Mushavi A, Mukungunugwa SH, Chimwaza A, et al. Viral load testing among women on 'option B+' in Mazowe, Zimbabwe: How well are we doing? PLoS One. 2019;14(12):1-14.
- 29. Chagomerana MB, Edwards JK, Zalla LC, Carbone NB, Banda GT, Mofolo IA, et al. 494 Timing of HIV testing among pregnant and breastfeeding women and risk of mother-495

491

492

497 2021;24(3):e25687.

- 30. Chohan BH, Ronen K, Khasimwa B, Matemo D, Osborn L, Unger JA, Drake AL, Beck 498
- IA, Frenkel LM, Kinuthia J, John-Stewart G. Food insecurity, drug resistance and non-499
- disclosure are associated with virologic non-suppression among HIV pregnant women 500
- on antiretroviral treatment. PloS one. 2021;16(8):e0256249. 501
- 502 31. Myer L, Essajee S, Broyles LN, Watts DH, Lesosky M, El-Sadr WM, et al. Pregnant
- and breastfeeding women: A priority population for HIV viral load monitoring. PLoS 503
- 504 Med. 2017;14(8):1-7.
- 32. Duri K, Mataramyura H, Chandiwana P, Mazhandu AJ. Mother-to-Child Transmission 505
- of HIV Within 24 Months After Delivery in Women Initiating Lifelong Antiretroviral 506
- Therapy Pre / Post-Conception or Postnatally; Effects of Adolescent Girl and Young 507
- Woman Status and Plasma Viremia Late in Pregnancy. Front Virol. 2022;2(906271). 508
- 10.3389/fviro.2022.906271. 509
- 33. Gordon TP, Talbert M, Mugisha MK, Herbert AE, Factors associated with HIV viral 510
- suppression among adolescents in Kabale district, South Western Uganda. Plos one. 511
- 2022;17(8):e0270855. 512
- 34. Erjino E, Abera ELTD. Time to Viral Load Suppression and Its Predictors Among 513
- Adult Patients on Antiretro Viral Therapy in Nigist Eleni Mohammed Memorial 514
- Comprehensive. HIV/AIDS Res Palliat Care. 2023;15 515
- (https://doi.org/10.2147/HIV.S408565):157–71. 516
- 35. Napyo A, Tumwine JK, Mukunya D, Tumuhamye J, Arach AAO, Ndeezi G, et al. 517
- Detectable HIV-RNA Viral Load Among HIV-Infected Pregnant Women on Treatment 518
- in Northern Uganda. Int J Matern Child Heal AIDS. 2020;9(2):232-41. 519

medRxiv preprint doi: https://doi.org/10.1101/2024.06.13.24308915; this version posted June 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license.

36. Ajao KO, Ojofeitimi EO, Adebayo AA, Fatusi AO, Afolabi OT. Influence of family size, household food security status, and child care practices on the nutritional status of under-five children in Ile-Ife, Nigeria. African journal of reproductive health. 2010;14(4). 37. Atuhaire P, Matovu F, Nakalega R, Kataike H, Nabwana M, Lukyamuzi Z, Guwattude D. Time to first viral load testing among pregnant women living with HIV initiated on option B+ at 5 government clinics in Kampala city, Uganda: Retrospective cohort study. International Journal of Infectious Diseases. 2021;104:526-31. 38. Langford SE, Ananworanich J, Cooper DA. AIDS Research and Therapy Predictors of disease progression in HIV infection: a review. AIDS Res Ther. 2007;4(11). 10.1186/1742-6405-4-11.

### **Tables and figures**

#### **Tables**

# Table 1: Socio-demographic characteristics of HIV-positive receiving ART drugs among pregnant and lactating women.

Variables	Category	Frequency	Percent
Age group	<30 years	265	53.4
	>=30 years	231	46.6
Educational	No formal education	81	16.3
status	Primary School	188	37.9
	Secondary School	153	30.8
	College/ University	74	14.9
Marital	Divorced	29	5.8
Status	Widowed	9	1.8
	Married	427	86.1
	Single	31	6.3
Religious	Orthodox Christian	384	77.4
Belief	Protestant	44	8.9
	Muslim	62	12.5
	Others	6	1.2
Occupational Status	Government and private employee	144	29.0
	Housewife	273	55.0
	Merchant	31	6.3
	Unemployed	36	7.3
	Others	12	2.4
Type of	Health Centre	332	66.9
health facility	Hospital	164	33.1
Family size	1-2	78	15.7
	3-4	285	57.5
	>4	133	26.8

Variables	Category	Frequency	Percent
Partner's HIV status	Negative	138	27.8
	Positive	244	49.2
	Unknown	114	23.0
Receiving regular supplies	No	41	8.3
of ART	Yes	455	91.7
Level of Adherence	Poor	11	2.2
	Fair	20	4.0
	Good	465	93.8
Opportunistic infection	No	461	92.9
exposed	Yes	35	7.1
WHO clinical stage	Stage III	11	2.2
	Stage II	24	4.8
	Stage I	461	92.9
Alcohol /substance use in	No	443	89.3
the last one month	Yes	53	10.7
HIV status disclosure other	No	133	26.8
than HCWs	Yes	363	73.2
The habit of using a memory	No	192	38.7
aid	Yes	304	61.3
Previous ART regimen	1B	2	0.6
(n=356)	1C (AZT + 3TC + NVP)	34	9.6
	1E (TDF + 3TC + EFV)	320	89.9
ART duration	6-11 months	53	10.7
	1 to 5 years	175	35.3
	5 to 10 years	165	33.3
	more than 10 years	103	20.8

Variables	Category	Frequency	Percent
Type of participants	Pregnant	176	35.5
	Lactating	320	64.5
Gestational Age	First Trimester	11	6.3
(n=176)	Second Trimester	81	46.0
	Third Trimester	84	47.7
Gravidity	Primigravida	194	39.1
	Multigravida	302	60.9
Parity	0-1 child	362	73.0
	>=2 child	134	27.0
Chronic Illness (at the	No	487	98.2
time of the survey)	Yes	9	1.8
MUAC	<23 cm	23	4.6
	>=23 cm	473	95.4
CD4 (time of survey)	<350 cells/ul	33	6.7
	>=350	463	93.3
Syphilis Antibody	Positive	14	2.8
test	Negative	482	97.2

#### Table 4: Chi-square analysis of factors associated with HIV-1 viral non-suppression among PMTCT Mothers.

Variables	Category	Viral non- suppressed N (%)	Viral suppressed N (%)	Chi- square (X²)	P- value
Type of health facility	Health Centre	6 (1.8)	326 (98.2)	0.780	0.377
	Hospital	5 (3.0)	159 (97.0)		
Age	<30 years	4 (1.5)	261 (98.5)		
	>=30 years	7 (3.0)	224 (97.0)	1.316	0.251
Educational status	No formal education	4 (4.9)	77 (95.1)		
	Primary School	3 (1.6)	185 (98.4)	3.765	0.288
	Secondary School	2 (1.3)	151 (98.7)		
	College/ University	2 (2.7)	72 (97.3)		
Marital Status	Divorced	2 (6.9)	27 (93.1)		
	Widowed	0 (0.0)	9 (100.0)	3.510	0.319
	Married	8 (1.9)	419 (98.1)		
	Single	1(3.2)	30 (96.8)		
Religious Belief	Orthodox Christian	9 (2.3)	375 (97.7)		
	Protestant	1 (2.3)	43 (97.7)	0.269	0.966
	Muslim	1 (1.6)	61 (98.4)		
	Others	0 (0.0)	6 (100.0)		
Occupational Status	Government and private	3 (2.1)	141 (97.9)		
	employee			5.409	0.248
	Housewife	4 (1.5)	269 (98.5)		
	Merchant	2 (6.5)	29 (93.5)		

	lt is made available under a C Unemployed	1 (2.8)	onal license to dis		
	Others	1 (8.3)	11 (91.7)		
Family Size	1-2	3 (3.8)	75 (96.2)		
	3-4	2 (0.7)	283 (99.3)	7.200	0.027*
	> 4	6 (4.5)	127 (95.5)		
Partner's HIV Status	Negative	5 (3.6)	133 (96.4)		
	Positive	2 (0.8)	242 (99.2)	4.332	0.115
	Unknown	4 (3.5)	110 (96.5)		
Receiving regular	No	2 (4.9)	39 (95.1)		
supplies of ART	Yes	9 (2.0)	446 (98.0)	1.459	0.227
Level of Adherence	Poor	1(9.1)	10 (90.9)		
	Fair	3 (15.0)	17 (85.0)	18.553	<0.001*
	Good	7 (1.5)	458 (98.5)		
Opportunistic	Yes	5 (14.3)	30 (85.7)		
infection	No	6 (1.3)	455 (98.7)	25.290	<0.001*
WHO clinical stage	Stage II & III	5 (14.3)	30 (85.7)		
	Stage I	6 (1.3)	455 (98.7)	25.290	<0.001*
Alcohol/substance use	Yes	3 (5.7)	50 (94.3)		
in the last one month	No	8 (1.8)	435 (98.2)	3.243	0.072
HIV status disclosure	No	6 (4.5)	127 (95.5)		
other than HCWs	Yes	5 (1.4)	358 (98.6)	4.408	0.036*
The habit of using a	No	5 (2.6)	187 (97.4)		
memory aid	Yes	6 (2.0)	298 (98.0)	0.216	0.642
Previous ART regimen	1B	0 (0.0)	2 (100.0)		
	1C (AZT + 3TC + NVP)	0 (0.0)	34 (100.0)	2.173	0.537
	1E (TDF + 3TC + EFV)	6 (1.9)	314 (98.1)	7	
ART duration	6-11 months	2 (3.8)	51 (96.2)		
	1 to 5 years	4 (2.3)	171 (97.7)	0.753	0.861
	5 to 10 years	3 (1.8)	162 (98.2)		
	more than 10 years	2 (1.9)	101 (98.1)		
Type of participants	Pregnant	4 (2.3)	172 (97.7)		
	Lactating	7 (2.2)	313 (97.8)	0.004	0.951
Gestational Age	First Trimester	0 (0.0)	11 (100.0)		
(n=176)	Second Trimester	0 (0.0)	81 (100.0)	4.483	0.106
	Third Trimester	4 (4.8)	80 (95.2)	7	
Gravidity	Primigravida	4 (2.1)	190 (97.9)		
•	Multigravida	7 (2.3)	295 (97.7)	0.036	0.850
Parity	0-1 child	7 (1.9)	355 (98.1)		
•	>=2 child	4 (3.0)	130 (97.0)	0.499	0.480
MUAC	<23 cm	1 (4.3)	22 (95.7)		
	>=23 cm	10 (2.1)	463 (97.9)	0.505	0.477
CD4	<350 cells/ul	4 (12.1)	29 (87.9)		
	>=350	7 (1.5)	456 (98.5)	15.989	<0.001*
Syphilis Antibody test	Positive	1 (7.1)	13 (92.9)		
	Negative	10 (2.1)	472 (97.9)	1.611	0.204

<sup>\*</sup>indicates p-value less than < 0.05

# **PMTCT Mothers**

Quantitative variables	HIV-1 Viral Non-	HIV-1 Viral Suppressed	P- value
	suppressed (N=11)	(N=485)	
Age, Median (IQR)	35 (30, 37)	30 (27, 35)	0.075
Duration on ART in			
months, Median	60 (15.5, 120)	72 (28, 120)	0.696
(IQR)			
MUAC measurement			
in cm, Median (IQR)	25 (23, 25.53)	25 (24, 26)	0.396
CD4 T cell in cells/ul,			
Median (IQR)	548 (278, 555)	555 (542, 563)	0.013*
Heamoglobin in g/dl,			
Median (IQR)	12.87 (12.2, 12.92)	12.88 (12.2, 13.5)	0.408

<sup>\*</sup>indicates the significance level < 0.05

### **Figures**




Figure 1: Proportion of participant's reason to stop/skip ART drugs within the last 6 months (n=211)




Figure 2: Proportions of ART drug regimen usage among PMTCT Mothers





Figure 3: Magnitude of HIV-1 non-suppression and Viral detectability among PMTCT Mothers



LLV: low-level viremia, ND: non-detectable

613

614

615616

617

Figure 4: Distribution of low-level viremia, viral non-suppression and viral detectability among PMTCT Mothers





Figure 5: Sunkey diagram of the reason for SKIP/Missed ART drugs and distribution of viral non-suppression among PMTCT Mothers.



MUAC: Middle upper circumference, CD4: Cluster cell differentiation, Hgb: Haemoglobin

Figure 6: Mean distributions of Quantitative variables in non-suppressed and suppressed PMTCT Mothers